TD Cowen lowered the firm’s price target on Novavax (NVAX) to $8 from $9 and keeps a Hold rating on the shares. The firm updated the company’s model post the Q2 results to reflect a 49% decrease in the number of U.S. adults eligible for COVID-19 boosters under a risk-based FDA label. TD believes positive results from Novavax’s recently initiated Phase 4 Nuvaxovid efficacy trial could bring share uipside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- NVAX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Unusually active option classes on open July 24th
- Novavax ‘s H5N1 vaccine candidate shows immunogenicity in preclinical study
- Novavax price target lowered to $9 from $10 at BofA
- Novavax’s Promising Vaccine Study: A Potential Game-Changer for COVID-19 and Flu